Performance and Safety of Bone Substitute MBCP-FS in Maxillary Sinus Lift Procedures
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to evaluate the performance and to monitor the safety of the bone substitute Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS) in Sinus Lift Procedures . This study will be conducted in two parts: part A evaluates safety and performance of MBCP-FS in bone regeneration i.e. the amount of new bone that is formed and its suitability for dental implant placement. Part B is designed to evaluate long-term safety and performance of the product, i.e. whether the newly-formed bone is suitable to retain implants.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written informed consent obtained from the subject prior to participation in the study
At least 18 years of age
Partially or totally edentulous with an atrophic posterior maxilla requiring unilateral or bilateral sinus lift before dental implant placement
In case of bilateral sinus lifts, both sides are operated on the same day.
Subjects with remaining minimal maxillary bone height between 2 mm and 5 mm at the site with minimal height in the area where implants are planned, and a remaining maxillary bone thickness >= 5 mm in the area where implants are planned
Previous or coeval major surgical intervention in the targeted area, or major surgical intervention in the targeted area planned within the next 18 months (like Caldwell Luc) (minor interventions like surgical tooth extraction or root tip resections are allowed)
Surgical tooth extraction in the targeted area less than three months before the SLP
Maxillary and sinus disorders including: acute sinusitis, chronic sinus pathology, retained root tips, polyps, tumors, and cysts in antral cavity or odontogenic cysts, alveolar scar ablation
Major occlusal disturbance, like severe bruxism
Uncontrolled* periodontal disease
An inadequate interarch distance requiring an oppositional graft
Immune system disorders, immunodeficiency or immunosuppression
Known coagulation disorder
Uncontrolled* diabetes mellitus
Receiving long-term anti-inflammatory treatment with NSAIDs or corticosteroids
Chemotherapy current or in the last three months
Having undergone maxillary radiation therapy
Known hypersensitivity to aprotinin or to other components of the investigational product
Abuse of alcohol or drugs or tobacco consumption of more than 5 cigarettes per day at study start
Non-compliant for future dental hygiene
Severely compromised physical and psychological health, that in the investigators opinion will affect patient compliance
Any contra-indications to the use of MBCP, which are defined as osteomyelitis, degenerative bone disease or necrosis of the recipient site
Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days
Pregnant or lactating, or intending to become pregnant during the study period
Uncontrolled = not treated or not stabilized after treatment